Nanjing Baixinyu Pharmaceutical Co., Ltd.

1) To evaluate the safety and tolerability of a single dose of 60 mg edaravone sublingual tablets in healthy subjects; 2) To evaluate the pharmacokinetic differences between a single dose of edaravone sublingual tablets (2 tablets, 30 mg/tablet) and edaravone injection (60 mg, intravenous infusion for 60 min) in healthy subjects; 3) To evaluate the safety, tolerability and pharmacokinetic characteristics of multiple doses of 60 mg edaravone sublingual tablets in healthy subjects.

To evaluate the efficacy and safety of edaravone sublingual tablets in the treatment of acute ischemic stroke

To evaluate the safety and tolerability of a single dose of edaravone sublingual tablets in healthy humans, to evaluate the pharmacokinetic differences between a single dose of edaravone sublingual tablets and edaravone injection in healthy humans, and to evaluate the safety, tolerability, and pharmacokinetic characteristics of multiple doses of edaravone sublingual tablets in healthy humans.